1-1 of 1
prolonged qt interval
Close
Sort by
Journal Articles

A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535)

Clinical Trials & Observations
Jeffrey E. Lancet, Anna B. Moseley, Steven E. Coutre, Daniel J. DeAngelo, Megan Othus, Martin S. Tallman, Mark R. Litzow, Rami S. Komrokji, Harry P. Erba, Frederick R. Appelbaum
Journal: Blood Advances
Blood Adv (2020) 4 (8): 1683–1689.
https://doi.org/10.1182/bloodadvances.2019001278
Published: 2020